Sesh develops a blood-based liquid biopsy intended to detect predictive cancer biomarkers from a simple blood draw to inform individualized treatment decisions. The company plans to commercialize that test and advance its broader precision oncology platform to help patients receive therapies most likely to benefit them. Sesh is led by founder and CEO Andrew Sinkoe, Ph.D., and operates out of San Diego. The company has received support from programs and organizations including Connect, EvoNexus, the National Cancer Institute, and the Brink San Diego & Imperial Small Business Development Center Network. Most recently, Sesh won the 2026 SDSU San Diego Angel Conference and secured a $200,000 investment to help fund its commercialization efforts.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026